The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus
Open accessAbstract
Background: Tacrolimus is metabolized predominantly to 13-O-demethyltacrolimus in the liver and intestine by cytochrome P450 3A (CYP3A). Patients with high concentrations of CYP3A5, a CYP3A isoenzyme polymorphically produced in these organs, require higher doses of tacrolimus, but the exact mechanism of this association is unknown. Methods: cDNA-expressed CYP3A enzymes and a bank of human liver microsomes with known CYP3A4 and CYP3A5 content were used to investigate the contribution of CYP3A5 to the metabolism of tacrolimus to 13-O-demethyltacrolimus as quantified by liquid chromatography–tandem mass spectrometry. Results: Demethylation of tacrolimus to 13-O-demethyltacrolimus was the predominant clearance reaction. Calculated Km and Vmax values for CYP3A4, CYP3A5, and CYP3A7 cDNA-expressed microsomes were 1.5 μmol/L and 0.72 pmol · (pmol P450)−1 · min−1, 1.4 μmol/L and 1.1 pmol · (pmol P450)−1 · min−1, and 6 μmol/L and 0.084 pmol · (pmol P450)−1 · min−1, respectively. Recombinant CYP3A5 metabolized tacrolimus with a catalytic efficiency (Vmax/Km) that was 64% higher than that of CYP3A4. The contribution of CYP3A5 to 13-O-demethylation of tacrolimus in human liver microsomes varied from 1.5% to 40% (median, 18.8%). There was an inverse association between the contribution of CYP3A5 to 13-O-demethylation and the amount of 3A4 protein (r = 0.90; P <0.0001). Mean 13-O-demethylation clearances in CYP3A5 high and low expressers, estimated by the parallel-tube liver model, were 8.6 and 3.57 mL · min−1 · (kg of body weight)−1, respectively (P = 0.0088). Conclusions: CYP3A5 affects metabolism of tacrolimus, thus explaining the association between CYP3A5 genotype and tacrolimus dosage. The importance of CYP3A5 status for tacrolimus clearance is also dependent on the concomitant CYP3A4 activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Pang, K. S., & Rowland, M. (1977) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059688 · Cited by 797 · cited 1×
“This was done according to the well-stirred (CLp1) and parallel-tube (CLp2) models (32, 33) and the respective, following equations ( 34 , 35):”
Method
Cited by
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, M., van Gelder, T., Åsberg, A., Haufroid, V., Hesselink, D. A., Langman, L., Lemaitre, F., Marquet, P., Seger, C., Shipkova, M., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000640 · Cited by 707
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Impact of Obesity on Drug Metabolism and Elimination in Adults and Children
Brill, M. J. E., Diepstraten, J., van Rongen, A., van Kralingen, S., van den Anker, J. N., & Knibbe, C. A. J. (2012) · Clinical Pharmacokinetics · doi:10.2165/11599410-000000000-00000 · Cited by 382
PharmGKB: The Pharmacogenomics Knowledge Base
Thorn, C. F., Klein, T. E., & Altman, R. B. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-435-7_20 · Cited by 358
EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
Dai, Y., Hebert, M. F., Isoherranen, N., Davis, C. L., Marsh, C., Shen, D. D., & Thummel, K. E. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008680 · Cited by 279
Metadata
- Authors
- Kamdem, L. K., Streit, F., Zanger, U. M., Brockmöller, J., Oellerich, M., Armstrong, V. W., & Wojnowski, L.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-01
- Volume
- 51
- Issue
- 8
- Pages
- 1374-1381
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2172057558
- Cited by
- 218
- References
- 2
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus. https://app.cochat.ai/papers/10.1373/clinchem.2005.050047
- The paper
- Kamdem, L. K., Streit, F., Zanger, U. M., Brockmöller, J., Oellerich, M., Armstrong, V. W., & Wojnowski, L. (2005). Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus. Clinical Chemistry. https://doi.org/10.1373/clinchem.2005.050047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.